- Case-Based Modules
- Initial Evaluation
- Dermatologic Manifestations
- Oral Manifestations
- OIs: Prophylaxis
- OIs: Treatment
- Antiretroviral Rx
- Antiretroviral Rx: Resistance
- Antiretroviral Rx: Adverse Effects
- Drug-Drug Interactions
- Postexposure Prophylaxis
- Perinatal Transmission
- Special Populations
- Prevention for Positives
- Challenging Unknowns
- Resource-Limited Settings
- Interactive Tutorials
- Routine HIV Screening
- Oraquick Advance Rapid HIV Test
- HIV Integration
- This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.
Antiretroviral Rx: Adverse Effects
Question | Discussion | References | CME Credit
Case 2: Nevirapine-Induced Hepatotoxicity
You answered:
 |
The patient likely has nevirapine-induced hepatotoxicity. Antiretroviral therapy should be temporarily discontinued until symptoms resolve and hepatic aminotransferase levels return to baseline. Nevirapine should not be used again for this patient. |
|---|
This answer is correct. The constitutional symptoms, laboratory abnormalities, and timing of the reaction indicate a probable nevirapine-induced hepatotoxicity. Patients often have systemic symptoms associated with nevirapine-induced hepatotoxicity. The proper course of management is to promptly discontinue nevirapine, and the patient should not receive nevirapine again. Treatment with corticosteroids is not recommended.
Copyright © 2004-2013 University of Washington